OTSUKA RECEIVES COMPLETE RESPONSE LETTER FOR EXTENDED-RELEASE INJECTABLE SUSPENSION OF ARIPIPRAZOLE

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced receipt of a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) to the New Drug Application (NDA) for the investigational intramuscular (IM) depot formulation of aripiprazole.  In the letter, the only issue FDA cited was deficiencies from a recent inspection of a third-party supplier of sterile water. 
 
Otsuka is working closely with the third-party supplier to resolve the issue as quickly as possible and is planning further discussions with the agency to determine next steps.
 
Financial guidance

The content of this release will have no influence on the Lundbeck Group's financial guidance for 2012, which was provided on 8 February 2012 in connection with the release of the financial results for 2011, and further specified in connection with the announcement of the restructuring plan on 14 June 2012. 

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.